260 related articles for article (PubMed ID: 22107842)
1. Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy.
Yagi H; Sanechika S; Ichinose H; Sumi-Ichinose C; Mizukami H; Urabe M; Ozawa K; Kume A
Neuroreport; 2012 Jan; 23(1):30-4. PubMed ID: 22107842
[TBL] [Abstract][Full Text] [Related]
2. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
3. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
Ding Z; Georgiev P; Thöny B
Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
[TBL] [Abstract][Full Text] [Related]
4. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
Oh HJ; Park ES; Kang S; Jo I; Jung SC
Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
[TBL] [Abstract][Full Text] [Related]
5. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector.
Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A
J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099
[TBL] [Abstract][Full Text] [Related]
6. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy.
Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627
[TBL] [Abstract][Full Text] [Related]
7. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer.
Nagasaki Y; Matsubara Y; Takano H; Fujii K; Senoo M; Akanuma J; Takahashi K; Kure S; Hara M; Kanegae Y; Saito I; Narisawa K
Pediatr Res; 1999 Apr; 45(4 Pt 1):465-73. PubMed ID: 10203136
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.
Fang B; Eisensmith RC; Li XH; Finegold MJ; Shedlovsky A; Dove W; Woo SL
Gene Ther; 1994 Jul; 1(4):247-54. PubMed ID: 7584088
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria.
Jung SC; Park JW; Oh HJ; Choi JO; Seo KI; Park ES; Park HY
J Korean Med Sci; 2008 Oct; 23(5):877-83. PubMed ID: 18955797
[TBL] [Abstract][Full Text] [Related]
10. Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy.
Chen L; Thung SN; Woo SL
Mol Ther; 2007 Jun; 15(6):1079-85. PubMed ID: 17406346
[TBL] [Abstract][Full Text] [Related]
11. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin.
Christensen R; Alhonen L; Wahlfors J; Jakobsen M; Jensen TG
Exp Dermatol; 2005 Jul; 14(7):535-42. PubMed ID: 15946242
[TBL] [Abstract][Full Text] [Related]
12. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
[TBL] [Abstract][Full Text] [Related]
13. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
Winn SR; Scherer T; Thöny B; Harding CO
Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of myocilin in the brain of a mouse model for phenylketonuria (PKU).
Surendran S; Matalon D; Tyring SK; Rady PL; Velagaleti GV; Matalon R
Neurosci Lett; 2005 Jul; 382(3):323-6. PubMed ID: 15925112
[TBL] [Abstract][Full Text] [Related]
15. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.
Ding Z; Harding CO; Rebuffat A; Elzaouk L; Wolff JA; Thöny B
Mol Ther; 2008 Apr; 16(4):673-81. PubMed ID: 18362925
[TBL] [Abstract][Full Text] [Related]
16. Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.
Winn SR; Scherer T; Thöny B; Ying M; Martinez A; Weber S; Raber J; Harding CO
Mol Genet Metab; 2018 Jan; 123(1):6-20. PubMed ID: 29331172
[TBL] [Abstract][Full Text] [Related]
17. [Pathogenetic mechanisms in phenylketonuria: disorders affecting the metabolism of neurotransmitters and the antioxidant system].
Ormazábal A; Artuch R; Vilaseca MA; García-Cazorla A; Campistol J
Rev Neurol; 2004 Nov 16-30; 39(10):956-61. PubMed ID: 15573314
[TBL] [Abstract][Full Text] [Related]
18. Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector.
Cerreto M; Mehdawy B; Ombrone D; Nisticò R; Ruoppolo M; Usiello A; Daniele A; Pastore L; Salvatore F
Curr Gene Ther; 2012 Feb; 12(1):48-56. PubMed ID: 22348550
[TBL] [Abstract][Full Text] [Related]
19. Of mice and men: Plasma phenylalanine reduction in PKU corrects neurotransmitter pathways in the brain.
Berguig GY; Martin NT; Creer AY; Xie L; Zhang L; Murphy R; Pacheco G; Bullens S; Olbertz J; Weng HH
Mol Genet Metab; 2019 Dec; 128(4):422-430. PubMed ID: 31648944
[TBL] [Abstract][Full Text] [Related]
20. Early-onset behavioral and neurochemical deficits in the genetic mouse model of phenylketonuria.
Fiori E; Oddi D; Ventura R; Colamartino M; Valzania A; D'Amato FR; Bruinenberg V; van der Zee E; Puglisi-Allegra S; Pascucci T
PLoS One; 2017; 12(8):e0183430. PubMed ID: 28850618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
